Safety and efficacy of air inhaled insulin compared with subcutaneous insulin in patients having diabetes and asthma: A 12-month, randomized, noninferiority trial

Diabetes Technology and Therapeutics

Volumn 11, Issue SUPPL. 2, 2009, Pages

  Ang, Ernesto ^a   Lawrence, Mary K ^b   Heilmann, Cory R ^c   Ferguson, Jeffrey A ^d   Tobian, Janet A ^d   Webb, David M ^d   Berclaz, Pierre Yves ^d  

^a Cardinal Santos Medical Center   (Philippines)

^b Down East Medical Associates   (United States)

^c US Medical Division   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AERX; AIR INHALED INSULIN; HEMOGLOBIN A1C; INSULIN; RECOMBINANT HUMAN INSULIN; UNCLASSIFIED DRUG;

ARTICLE; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; GLYCEMIC CONTROL; HUMAN; LUNG; PRIORITY JOURNAL;

ADMINISTRATION, INHALATION; ADULT; AGE OF ONSET; AGED; ASTHMA; BODY MASS INDEX; CARBON MONOXIDE; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; FORCED EXPIRATORY VOLUME; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INJECTIONS, SUBCUTANEOUS; INSULIN; MALE; MIDDLE AGED; SMOKING; VITAL CAPACITY;

EID: 70349462771     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2009.0054     Document Type: Article

References (36)

1. Byron PR: Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J Pharm Sci 1986;75:433-438.
2. Korytkowski M: When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002; 26(Suppl 3):S18-S24.
3. Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, Landgraf R, Kleinebreil L; the International DAWN Advisory Panel: Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005;28:2673-2679.
4. Hayes RP, Bowman L, Monahan PO, Marrero DG, McHorney CA: Understanding diabetes medications from the perspective of patients with type 2 diabetes: prerequisite to medication concordance. Diabetes Educ 2006;32:404-414.
5. Siegel K, Narayan KV: The Unite for Diabetes campaign: overcoming constraints to find a global policy solution. Global Health 2008;4:3.
6. Braman SS: The global burden of asthma. Chest 2006;130 (1 Suppl):4S-12S.
7. Masoli M, Fabian D, Holt S, Beasley R; Global Initiative for Asthma (GINA) Program: The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004;59:469-478.
8. Ellis SL, Gemperline KA, Garg SK: Review of phase 2 studies utilizing the AIR particle technology in the delivery of human insulin inhalation powder versus subcutaneous regular or lispro insulin in subjects with type 1 or type 2 diabetes. Diabetes Technol Ther 2007;9(Suppl 1):S48-S56.
9. Garg S, Rosenstock J, Silverman BL, Sun B, Konkoy CS, de la Pena A, Muchmore DB: Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes. Diabetologia 2006;49:891-899.
10. Wolzt M, de la Peña A, Berclaz PY, Tibaldi FS, Gates JR, Muchmore DB: AIR inhaled insulin versus subcutaneous insulin: pharmacokinetics, glucodynamics, and pulmonary function in asthma. Diabetes Care 2008;31:735-740.
11. World Health Organization: Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications: Report of a WHO Consultation. Part 1, Diagnosis and Classification of Diabetes Mellitus. Geneva: World Health Organization, 1999.
12. Crapo RO, Casaburi R, Coates AL, Enright PL, Hankinson JL, Irvin CG, MacIntyre NR, McKay RT, Wanger JS, Anderson SD, Cockcroft DW, Fish JE, Sterk PJ: Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 2000;161:309-329.
13. Standardization of spirometry, 1994 update. American Thoracic Society. Am J Respir Crit Care Med 1995;152:1107-1136.
14. The Criteria Committee of the New York Heart Association: Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels, 9th ed. Boston, MA: Little, Brown & Co., 1994:253-256.
15. Rodbard HW, Blonde L, Braithwaite SS, Brett EM, Cobin RH, Handelsman Y, Hellman R, Jellinger PS, Jovanovic LG, Levy P, Mechanick JI, Zangeneh F; AACE Diabetes Mellitus Clinical Practice Guidelines Task Force: American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007;13(Suppl 1):1-68.
16. D'Orazio P, Burnett RW, Fogh-Andersen N, Jacobs E, Kuwa K, KÜlpmann WR, Larsson L, Lewenstam A, Maas AH, Mager G, Naskalski JW, Okorodudu AO; IFCC-SD-WGSEPOCT: Approved IFCC recommendation on reporting results for blood glucose: International Federation of Clinical Chemistry and Laboratory Medicine Scientific Division, Working Group on Selective Electrodes and Point-of-Care Testing (IFCC-SD-WG-SEPOCT). Clin Chem Lab Med 2006;44:1486-1490.
17. Mathieu C, Cuddihy R, Arakaki R, Belin RM, Planquois J-M, Lyons JN, Heilmann CR: A comparison between simplified and intensive dose-titration algorithms using AIR inhaled insulin for insulin-naive patients with type 2 diabetes in a randomized noninferiority trial. Diabetes Technol Ther 2009; 11(Suppl 2):S-53-S-61.
18. Garg SK, Mathieu C, Rais N, Gao H, Tobian JA, Gates JR, Ferguson JA, Webb DM, Berclaz P-Y: Two-year efficacy and safety of AIR inhaled insulin in patients with type 1 diabetes: an open-label randomized controlled trial. Diabetes Technol Ther 2009;11(Suppl 2):S-5-S-16.
19. Comulada AL, Renard E, Nakano M, Rais N, Mao X, Webb DM, Milicevic Z: Efficacy and safety of AIR inhaled insulin compared to insulin lispro in patients with type 1 diabetes mellitus in a 6-month, randomized, noninferiority trial. Diabetes Technol Ther 2009;11(Suppl 2):S-17-S-25.
20. American Thoracic Society: Single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique-1995 update. Am J Respir Crit Care Med 1995;152:2185-2198.
21. Heise T, Bott S, Tusek C, Stephan JA, Kawabata T, Finco- Kent D, Liu C, Krasner A: The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin: a prospective randomized pharmacodynamic study. Diabetes Care 2005;28:2161-2169.
22. Moxness M, Foley J, Stene M, Finco-Kent D, Bedian V, Krasner A, Kawabata T: Development and validation of radioligand binding assays to measure total, IgA, IgE, IgG, and IgM insulin antibodies in human serum. Ann N Y Acad Sci 2003;1005:265-268.
23. Henry RR, Mudaliar SR, Howland WC III, Chu N, Kim D, An B, Reinhardt RR: Inhaled insulin using the AERx Insulin Diabetes Management System in healthy and asthmatic subjects. Diabetes Care 2003;26:764-769.
24. Rave K, de la Peña A, Tibaldi FS, Zhang L, Silverman B, Hausmann M, Heinemann L, Muchmore DB: AIR inhaled insulin in subjects with chronic obstructive pulmonary disease: pharmacokinetics, glucodynamics, safety, and tolerability. Diabetes Care 2007;30:1777-1782.
25. Teeter JG, Foutaine R, Milton A, Wei G, Checchio T, Stolar M, Fryburg DA: Effects of albuterol and fluticasone on inhaled human insulin (Exubera-) pharmacokinetics in subjects with mild-to-moderate asthma [abstract]. Diabetologia 2006;49:116.
26. Barnett AH, Lange P, Dreyer M, Serdarevic-Pehar M: Longterm tolerability of inhaled human insulin (Exubera) in patients with poorly controlled type 2 diabetes. Int J Clin Pract 2007;61:1614-1625.
27. Gross JL, Nakano M, Colon-Vega G, Ortiz-Carasquillo R, Ferguson JA, Althouse S, Tobian JA, Berclaz P-Y, Milicevic Z: Initiation of prandial insulin therapy with AIR inhaled insulin or insulin lispro in patients with type 2 diabetes: a randomized noninferiority trial. Diabetes Technol Ther 2009; 11(Suppl 2):S-27-S-34.
28. Hollander PA, Blonde L, Rowe R, Mehta AE, Milburn JL, Hershon KS, Chiasson JL, Levin SR: Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6- month, randomized, comparative trial. Diabetes Care 2004; 27:2356-2362.
29. Rosenstock J, Cefalu WT, Hollander PA, Belanger A, Eliaschewitz FG, Gross JL, Klioze SS, St Aubin LB, Foyt H, Ogawa M, Duggan WT: Two-year pulmonary safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 2 diabetes. Diabetes Care 2008;31:1723-1728.
30. Rosenstock J, Eliaschewitz FG, Heilmann CR, Muchmore DB, Hayes RP, Belin RM: Comparison of prandial AIR inhaled insulin alone to intensified insulin glargine alone and to AIR insulin plus intensified insulin glargine in patients with type 2 diabetes previously treated with once-daily insulin glargine. Diabetes Technol Ther 2009;11(Suppl 2):S-63-S-73.
31. Quattrin T, Bélanger A, Bohannon NJ, Schwartz SL; Exubera Phase III Study Group: Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004;27:2622-2627.
32. Skyler JS, Weinstock RS, Raskin P, Yale JF, Barrett E, Gerich JE, Gerstein HC; Inhaled Insulin Phase III Type 1 Diabetes Study Group: Use of inhaled insulin in a basal=bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial. Diabetes Care 2005;28:1630-1635.
33. Russell-Jones D, Khan R: Insulin-associated weight gain in diabetes-causes, effects and coping strategies. Diabetes Obes Metab 2007;9:799-812.
34. Fineberg SE, Kawabata T, Finco-Kent D, Liu C, Krasner A: Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial. J Clin Endocrinol Metab 2005;90:3287-3294.
35. Teeter JG, Riese RJ: Dissociation of lung function changes with humoral immunity during inhaled human insulin therapy. Am J Respir Crit Care Med 2006;173:1194-1200.
36. Silverman BL, Barnes CJ, Campaigne BN, Muchmore DB: Inhaled insulin for controlling blood glucose in patients with diabetes. Vasc Health Risk Manag 2007;3:947-958.